← Back to Search

Virus Therapy

INO-3107 for Respiratory Papillomatosis

Phase 1 & 2
Waitlist Available
Research Sponsored by Inovio Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening up to week 52 (up to approximately 1 year)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing INO-3107, a treatment designed to create a strong immune response against specific proteins of HPV6. It aims to help people with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and/or HPV-11, including both children and adults.

Eligible Conditions
  • Recurrent Respiratory Papillomatosis (RRP)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening up to week 52 (up to approximately 1 year)
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening up to week 52 (up to approximately 1 year) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Secondary study objectives
Change in RRP Staging Assessment Scores Over Time

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: INO-3107Experimental Treatment2 Interventions
Participants will be administered one INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INO-3107
2020
Completed Phase 2
~40
CELLECTRA™ 2000
2020
Completed Phase 2
~480

Find a Location

Who is running the clinical trial?

Inovio PharmaceuticalsLead Sponsor
53 Previous Clinical Trials
4,773 Total Patients Enrolled
Jeffrey Skolnik, MDStudy DirectorInovio Pharmaceuticals
12 Previous Clinical Trials
662 Total Patients Enrolled
~6 spots leftby Dec 2025